

centages of only 1.1, 11, and 14%, whereas the remaining 4 children had no lymphocyte transformation at all. Again, the lymphocytes obtained from the spinal fluid in 3 evaluable patients of 7 examined, all affected by meningeal leukemia, and from the pleural effusion in 1 patient did not undergo any blastic transformation. It appears that a quite different behavior concerning P11A blastogenesis of lymphocytes in ALL can be observed according to the source the lymphocytes come from.

66. *In vitro* sensitivity to vincristine of acute lymphocytic leukemia cells—a tentative to correlate *in vivo* and *in vitro* results. L. PICENI SERENI, G. MASERA, V. CARNELLI, and F. SERENI, *Univ. of Milan, Italy*.

Data were obtained on the influence of vincristine ($7 \times 10^{-5}M$) on the *in vitro* incorporation of both $6\text{-}^{14}C$ -orotate into RNA and of $1\text{-}^{14}C$ -leucine into proteins of leukemic cells from acute lymphocytic leukemia. Orotate and leucine incorporations were measured after 2 and 12 hr of incubation. A total of 17 patients were examined. Most of the *in vitro* studies were conducted on peripheral blast cells. In 4 instances also bone marrow leukemic cells were tested. In any case in which a good clinical response by vincristine administration was recorded, also a strong *in vitro* inhibition of both RNA and protein synthesis was observed. On the contrary, in the only 2 cases in which a definitive *in vivo* resistance to vincristine was observed, also an *in vitro* lack of response was found. Practical implications of these studies will be discussed.

67. Gluconeogenesis in human platelets. K. A. ZUPPINGER, N. NAKAMURA, J. P. COLOMBO, and P. WALTER, *Universitäts-Kinderklinik and Univ. of Bern, Switzerland*.

Quantitative evaluation of gluconeogenesis in humans is difficult since liver and kidney are not suitable for repeated investigation. Therefore, gluconeogenesis in easily available tissue such as platelets was studied during incubation in buffered solution. Upon addition of 20 mM pyruvate glucose formation in the incubation medium amounted to $6.99 \mu\text{moles/hr } 10^{11}$ platelets and glycogen utilization was inhibited to 28.8%. Incorporation of label from pyruvate- $2\text{-}^{14}C$ into carbohydrates revealed $2.22 \mu\text{moles pyruvate incorporated/hr } 10^{11}$ platelets. These results are interpreted as evidence for the existence of gluconeogenesis in human platelets. In two patients with glycogen storage disease type I incorporation of label from pyruvate- $2\text{-}^{14}C$ into carbohydrates was decreased to $0.95 \mu\text{mole/hr } 10^{11}$ platelets. Only 7% of the total radioactivity was found to be in glucose in these patients as compared to 81% in normals, indicating that most radioactivity was incorporated into nonglucose carbohydrates, probably glycogen. Incorporation of label from pyruvate- $2\text{-}^{14}C$ into carbohydrates by platelets of two patients with glycogen storage disease type III showed no increase in comparison to normals; however, in these patients 95% of the label was found in glucose. This finding indicates that in type III glycogenosis a greater relative part of pyruvate is incorporated into glucose than in normals. The conclusion is drawn from these studies that human platelets might prove to be a valuable material for studying gluconeogenesis under various conditions.

INDEX OF ABSTRACTS

(Numbers following entries refer to abstract numbers)

- | | | |
|--|----------------------------|--------------------------------|
| AAGENALS, O. 47 | Blackfan-Diamond anemia 53 | Celiac disease 7 |
| Acidosis, lactate 11 | Blood-brain barrier 42 | Cell growth 21 |
| Acute leukemia 64 | BODEGÅRD, G. 35 | Central nervous system 32, 42 |
| Adenosine triphosphatase deficiency 62 | Body composition 17 | Chemotherapy 28 |
| Adrenal gland 44 | Body temperature 41 | Chemotherapy, cancer 28 |
| Alanine 10 | BORSSÉN, R. 30 | CHESSELLS, J. M. 58 |
| Albumin 54 | BOTTINI, E. 63 | CHOFFAT, J. M. 38 |
| Alkaline phosphatase 55 | Brain 19 | Cholestasis 47 |
| ALTMAN, V. 23 | Brain growth 33 | Chondroitinsulfate 1 |
| Amino acid metabolism 43 | BRALLID, D. 54 | CLAUSEN, J. 14 |
| Amino acids 16, 19 | BROUGHTON-PIPKIN, F. 49 | COHN, J. 62 |
| ANAGNOSTAKIS, D. 20 | Brush border 9 | COLOMBO, J. P. 67 |
| Anemia 62, 64 | BUCCI, G. 13 | COLOMBO, U. 13 |
| Angiokeratoma 2 | BURGIO, G. R. 24 | Color blindness 46 |
| Angiotensin II-like activity 49 | BURKE, V. 8 | Coomb's test 57 |
| ASTALDI, G. 65 | Cancer, kidney 48 | CORBEEL, L. M. 4 |
| AURICCHIO, S. 9 | Cancer, liver 48 | CUDERMAN, B. 47 |
| AURICCI, G. 26 | Capillary permeability 37 | CURRIE, G. 28 |
| BACCOLA, D. 48 | Carbohydrate metabolism 67 | CURTONI, E. 24 |
| BARTELS, H. 59 | CARNELLI, V. 66 | Cystathionase 19 |
| Bile, flow 47 | Carnosinase 3 | Cystathionine synthase 19 |
| Bilirubin 54, 57 | Cat urine disease 5, 6 | Cystic fibrosis of pancreas 10 |
| | | Cystine 19 |

- DAGNA-BRIGARELLI, F. 65
 DAVIES, P. A. 33
 Delayed hypersensitivity 24
 Dermatoglyphics 50
 DESJEUX, J. F. 10
 DESNICK, R. J. 2
 Developmental physiology 16, 35, 36, 37, 42
 Diarrheal disease 7
 DIETRICH, M. 25
 Dinitrophenyl antibodies 23
 Dipeptiduria 3
 DONATH, A. 17
 DUBOIS, J. 16
 DUPUY, J. M. 27
- EUCKELS, R. 4
 EGAN-MITCHELL, B. 7
 EGGERMONT, E. 4
 EKELUND, H. 39
 ELDJARN, L. 5, 6
 Enzyme therapy 2
 Epinephrine test 44
 Erythrocyte kinetics 61
 Erythrocytes 56
 Erythrocytic acid phosphatases 63
 Erythrophilic IgG-globulin coat 56
 Erythropoiesis 52, 64
 Erythropoietic inhibitors 52
Escherichia coli, antibodies 30
 EVANS, C. A. N. 42
 Exchange transfusion 57, 58, 60
- Fabry's disease 2
 Fat, body content 17
 Fat, intravenous infusions 15
 Fatty acids 14
 Favism 63
 α_1 -Fetoprotein 20
 Fetus 18, 19, 23, 37, 51
 Fibrinolysis 39
 Fibrinolytic system 39
 FINSSIRÖM, O. 31, 39
 FLAD, H.-D. 25
 FLIEDNER, T. M. 25
 FOG, J. 54
 FOSSATI-GUGLIELMONI, A. 65
 Free anti-D antibodies 57
 FRENCK, N. 38
 Friend virus-induced leukemia 27
 FRIIS-HANSEN, B. 14
 Fructose, absorption 8
- Galactosyl-galactosyl-glycosyl ceramide 2
 Galactosyl hydrolase 2
 GARWICZ, S. 53
 GAULL, G. E. 19
 Genetic disease 1, 2, 3, 5, 11, 12, 22, 53, 60, 62
 GENOVA, R. 24
 GENSCHER, U. 25
 Gestational age 20, 31, 33, 38, 39
- Glomerulonephritis 29
 Gluconeogenesis 67
 Glucose 6-phosphate dehydrogenase 63
 Glucose 6-phosphate dehydrogenase deficiency 46
 Glutathione deficiency 60
 Glycogen storage disease, types I, II 67
 Goiter, congenital 12
 GOOD, R. A. 27
 GRACEY, M. 8
 Growth 16
 Growth retardation 7, 13, 21, 34
 GUSTAFSON, A. 15
- HALVORSEN, S. 52
 HANEL, K. H. 62
 HANSON, L. Å. 30
 HARVENGT, C. 4
 Head, circumference 33
 Heat, body 40
 Hemolytic anemia 60
 Hemorrhage 58
 Hemosiderosis 53
 Heparitinsulfate 1
 Hering-Breuer reflex 35
 HINZE, G. 32
 HITZIG, W. H., 29, 60
 HJELM, M. 61
 HOCHAPPEL, G. 25
 HOHENAUFER, L. 34
 HOLMGREN, J. 30
 HÖYERKAL, H. M. 61
 Hyaline membrane disease 38
 β -Hydroxyisovaleric aciduria 5
 Hyperbilirubinemia 52, 56
 Hypercalciuria 45
 Hypercapnia 42
 Hyperlactacidemia 11
 Hyperpropionic acidemia 4
 Hypoglycemia 32, 44
 Hypophosphatasia 50
 Hypoplastic anemia, congenital 53
 Hypothyroidism 12
 Hypoxia 51
- IgA 22
 IgE 23
 IgM 22
 Immune isohemagglutinins 56
 Immunoglobulin deficiency 22
 Immunoglobulins 23
 Immunotherapy, cancer 28
 Infants 20, 43, 58
 Infants, low birth weight 13, 14, 15, 33, 39
 Infants, premature 35, 38, 39
 Infants, small for date 31, 32
 Intrauterine growth 13
 Intrauterine undernutrition 34
 Intravascular coagulation 58
 Isoenzyme patterns 59
- Jejunal mucosa 7
 JELLUM, E. 5, 6
 JÉQUIER, E. 40
 JODAL, U. 30
 JOSS, E. E. 44
- KAJSER, B. 30
 KARAKLIS, A. 46
 KÄSER, H. 44
 KEKOMÄKI, M. 18
 Ketotic hyperglycinemia 4
 Kidneys 29, 45
 KJELLMER, I. 15
 KLOSSNER, J. 41
 KLUBJER, L. 50
 KOIVIKKO, A. 41
 KOUVALAINEN, K. 55
 KRIEGER, D. 25
 KRIVYT, W. 2, 47
- Lactate, metabolism 11
 LÄNSIMIES, E. 41
 LARDINOIS, R. 20
 Lean body mass 17
 Leucine degradation 5
 Leucine metabolism 6
 Leukemia 26, 27
 LEVIN, S. 23
 LIE, S. O. 11, 54
 LINDEMANN, R. 52
 Lipid pattern 14
 β -Lipoprotein 14
 Liver 18, 19
 LO, S. S. 60
 Lungs 35, 36, 37, 38
 Lymphoblastic leukemia 65
 Lymphocytes 47, 65
 Lymphocyte transformation 65
 Lymphocytic leukemia 66
 Lymph vessel hypoplasia 47
 Lysosome 1
- MAGRINI, U. 24
 Malabsorption, glucosegalactose 8
 Malabsorption, monosaccharide 8
 Malnutrition, fetal 32
 MAPES, C. A. 2
 MARI, H. R. 60
 MARINI MAURI, M. 48
 MASERA, G. 66
 MASSIMO, L. 65
 MATOHL, Y. 51, 64
 MATSANIOTIS, N. 56
 Maturation 20
 Maturation, neurological 31
 McNICHOIL, B. 7
 MÉHES, K. 50
 Membrane transport 10
 MENDEINI, M. 13
 Mental retardation 1, 3, 34
 MESTYÁN, J. 43

- Methionine-activating enzyme 19
 β -Methylcrotonyl-CoA carboxylase 5
 β -Methylcrotonylglycine 6
 β -Methylcrotonylglycinuria 5
 MOE, P. J. 61
 MORI, P. G. 65
 MORIN, C. L. 10
 MOTT, J. C. 49
 Mucopolysaccharides 1
 MUSSA, G. C. 48

 NAKAMURA, N. 67
 NEUFELD, E. F. 1
 Newborns 13, 35, 36, 39, 40, 52, 56, 57
 NORMAND, I. C. S. 37

 Obesity 17
 β -OH-isovaleric acid 6
 OLEGÅRD, R. 15
 OLIN, P. 12
 OLSSON, T. 36
 OLVER, R. E. 37
 ORSATTI, M. 9
 ORTIZ, M. 20
 OSHIN, A. 8
 Oxygen transport 41

 PANDE, H. 6
 PANTILAKIS, S. N. 46
 PATAKI, L. 57
 Penicillin 23
 PELKONEN, P. 22
 Peptidase, intestinal 9
 Phosphopyruvate hydratase 59
 Phytohemagglutinin test 24
 PIGENI SERENI, L. 66
 PIERRO, M. 9
 Placenta 51
 Placental infarction 43
 Platelets 67
 PLENERI, W. 26
 PLÜSS, H. I. 29
 PORETTI, G. 17
 Pre- β -lipoproteins 15
 Protein synthesis 18
 PROD'HOM, L. S. 38
 Pyelonephritis 30, 45
 Pyruvate 67
 Pyruvate kinase 59
 Pyruvate kinase deficiency 61

 RAJHA, N. C. R. 19
 Renal tubular acidosis 45
 Respiration 36
 Respiratory distress syndrome 38
 Respiratory reflex, thoracic 35
 REYNOLDS, F. O. R. 37
 REYNOLDS, J. 42
 REYNOLDS, M. 42
 REZZA, E. 13
 Rh factor 57
 Rh factor isoimmunization 58
 ROBERTON, N. R. C. 49
 RUUSKANEN, O. 55
 RYSER, G. 40

 Saliva, cystic fibrosis of pancreas 10
 Salt-water homeostasis 16
 SAUNDERS, N. R. 42
 SAVILAHTI, E. 22
 SCHÄRER, K. 45
 SCHREMPF, G. 32
 SCHRETTEN, E. D. A. M. 3
 SCHULTE, F. G. 32
 SCHWARTZ, A. L. 18
 SCHWIELER, G. H. 35
 Scintiscanning 48
 SEGAL, M. B. 42
 SELA, M. 23
 SELSTAM, U. 36
 SEPPÄLÄ, M. 18
 SERENI, F. 66
 SHARP, H. 47
 SIGSTAD, H. 47
 Skeletal muscle, composition 16
 Skin 24
 Skin, composition 16
 SKJAEELAAEN, P. 52
 SKREDE, S. 11
 Small intestine 8
 Spinal muscular atrophy, infantile 6
 STAUFFER, U. G. 29
 Steatorrhea 7
 STOKKE, O. 5, 6
 STRANG, L. B. 37
 Streptokinase test 24
 STRØMME, J. H. 11
 STURMAN, J. A. 19
 STUTMAN, O. 27

 SVENNINGSEN, N. W. 53
 SWEELEY, C. C. 2

 TELLER, W. 25
 THOMASIDIS, T. 56
 Thymocytes 55
 Thymus 55
 Thymus, fetal 25
 Thymus "hormone" 25
 Thyroglobulin 12
 Thyroid hormone 12
 TIETZE, H. U. 44
 TORRADO, A. 38
 Toxemia, pregnancy 32, 43
 Transfusion, intraperitoneal 58
 Transfusion, intrauterine 58
 Transplantation antigens 26
 TREPPEL, F. 25
 TRIJBELS, J. M. F. 3
 Turner's syndrome 46
 Twins 34

 Umbilical circulation 43
 UNGARI, S. 13

 VALASSI-ADAM, H. 56
 VAN DRIESCHE, R. 4
 VAN HEFSWIJK, P. J. 3
 VAN MUNSTER, P. J. J. 3
 Ventriculoatrial shunt 29
 VICTORIN, I. 15
 VIS, H. L. 16
 Vitamin E 14

 WAALER, P. E. 6
 WALTER, P. 67
 Werdnig-Hoffman's disease 5, 6
 Whole body counter 17
 WIESMANN, U. N. 1
 WIGGLESWORTH, J. S. 21, 58

 X chromosome 46
 Xg blood group 46

 ZAIZOV, R. 51, 64
 ZINTL, F. 26
 ZUPPINGER, A. 17
 ZUPPINGER, K. A. 44, 67
 ZURBRÜGG, R. P. 44